预约演示
更新于：2026-05-16
Hydromorphone Hydrochloride
盐酸氢吗啡酮
更新于：2026-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-01-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20ClNO3 |
InChIKeyXHILEZUETWRSHC-NRGUFEMZSA-N |
CAS号71-68-1 |
关联
376
项与 盐酸氢吗啡酮 相关的临床试验ChiCTR2600119589
A randomized, open label, controlled multicenter clinical study comparing the safety and efficacy of hydromorphone sustained-release tablets and hydrocodone sustained-release tablets in the treatment of elderly cancer pain patients in China
ChiCTR2600123852
Comparison of Analgesic Efficacy and Opioid-Related Adverse Effects Between Oliceridine and Hydromorphone in Elderly Patients Undergoing Lumbar Spine Surgery: A Randomized, Controlled, Non-Inferiority Clinical Trial
ChiCTR2600123148
Analysis of the Efficacy of Different Doses of Dexmedetomidine Combined with Hydromorphone in Postoperative Pain Management for Lung Cancer
100 项与 盐酸氢吗啡酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸氢吗啡酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸氢吗啡酮 相关的专利（医药）
登录后查看更多信息
3,301
项与 盐酸氢吗啡酮 相关的文献（医药）2026-06-01Exploratory research in clinical and social pharmacy
Physicochemical compatibility and stability of ketamine co-administered with selected supportive care drugs and parenteral nutrition in pediatric oncology
Article
作者: Sunderland, Bruce ; Isaac, Emily ; Luna, Giuseppe ; Varonen, Katriina ; Czarniak, Petra ; Martinez, Jorge ; Soggee, Johnathan
Purpose:
Ketamine has been previously administered as an anesthetic but recently gained importance as an analgesic in pediatric oncology. Despite its efficacy, continuous intravenous administration to children with cancer is interrupted when other essential drugs require infusion. This occurs because its compatibility with many drugs and lipid emulsions is unknown, causing inadequate pain management and patient discomfort. This study has assessed the physicochemical compatibility and stability of ketamine with selected drugs, based on usage frequency data, and lipid emulsion formulations administered to pediatric cancer patients at tertiary hospitals.
Methods:
Physicochemical compatibility of ketamine involved admixture with selected concentrations of drugs, for physical incompatibility. Admixtures of ketamine with lipid emulsions and the other drugs included determining ketamine's chemical concentration using high performance liquid chromatography (HPLC). Particle size analysis investigated lipid stability.
Results:
The HPLC assay was linear over a range of concentrations (0.05 mg/mL - 0.5 mg/mL), validated under forced degradation conditions causing no interferences and an intra- and inter-day precision less than 2%. Ketamine was highly stable with all drugs and lipid emulsions tested, retaining >90% of its concentration for all systems investigated for two hours. No additional physical incompatibility occurred., but amoxicillin incompatibility was confirmed. Lipid emulsion stability was maintained, with no system exceeding particle size limits.
Conclusions:
Ketamine is safe to co-administer with AmBisome®, cyclizine, hydromorphone, Intralipid®, magnesium sulfate, metoclopramide, micafungin, potassium dihydrogen phosphate, sodium dihydrogen phosphate and vancomycin. Our findings are significant for improving pain management in vulnerable patients simultaneously administered the tested drugs with ketamine.
2026-06-01Addictive behaviors reports
The efficacy and safety of short-acting, full agonist opioids for symptom management of opioid withdrawal
Review
作者: Lau, Anthony ; Kim, Jane J ; Budd, George ; Azar, Pouya ; Wong, Jade ; Siu, Jacky T P ; Machado, Jessica ; Baldwin, Kaitlyn
INTRODUCTION:
Patients with opioid use disorder often have undertreated withdrawal while in hospital, leading to high rates of premature discharges. Short-acting, full agonist opioids (SAFAOs) have been proposed to alleviate withdrawal symptoms when provided as adjuncts to opioid agonist therapy (OAT). We aimed to synthesize evidence on the safety and efficacy of SAFAOs.
METHODS:
We searched the scientific databases MEDLINE, Embase, CINAHL, PsycInfo, Web of Science Core Collection, and the Cochrane Library for studies with adults whose opioid withdrawal symptoms were treated with SAFAOs. Results were narratively synthesized.
RESULTS:
Our search yielded 5,616 papers screened and 15 studies included. Information was gathered mostly from patient charts, followed by cohort studies, a cross-sectional study, and a clinical trial. Hydromorphone, tramadol, fentanyl, and oxycodone were described individually or as groupings to reduce withdrawal from heroin or fentanyl, initiate OAT, or as a bridge to transition between medications. Most studies observed reduced withdrawal scores and fewer occurrences of premature discharges in those who received these medications. Oversedation was observed as an adverse event in patients with ongoing opioid use.
DISCUSSION:
This systematic review provides an up-to-date synthesis on the use of SAFAOs to treat withdrawal. Our results suggest that in-hospital use of SAFAOs can reduce patient suffering and potentially the following risk for premature discharges. More clinical studies are needed to further investigate the clinical utility of SAFAO as a combination treatment with OAT.
2026-06-01PEDIATRIC BLOOD & CANCER
Low‐Dose Intravenous Ketamine for Primary Pain Control During Naxitamab Anti‐GD2 Immunotherapy Treatment
Article
作者: Szabo, Julienne ; Fernandez, Nicole ; Silber, Rosanna ; Modak, Shakeel ; Record, Benjamin ; Greenfield, Dana ; Hahn, Emily
ABSTRACT:
Background:
Anti‐GD2 antibodies, including naxitamab, are part of standard therapy for high‐risk neuroblastoma (HR‐NB) and are associated with significant pain. We developed a protocol for outpatient use of low‐dose intravenous ketamine (LDIVK) for pain management during naxitamab. We describe the LDIVK protocol and report on its impact on the management of naxitamab‐associated pain.
Methods:
Patients with HR‐NB receiving naxitamab with poorly controlled pain in at least 1 cycle received LDIVK outpatient for subsequent cycles. LDIVK at 0.5 mg/kg/h was started 30 minutes before and ended 1 hour after naxitamab. A retrospective chart review of LDIVK‐treated patients was completed. Intrapatient comparison of vital signs, opioid use, and adverse events between LVIDK‐containing and non‐containing cycles was analyzed using the Wilcoxon signed rank test.
Results:
Twenty‐two pediatric patients received LDIVK at a median age of 6.3 (range, 1–16) years. Twelve patients received the same premedication for cycles with and without LDIVK, and their opioid use was analyzed. Statistically significant reduction in total opioid use in LDIVK‐containing cycle (0.064 mg/kg IV hydromorphone vs. 0.054 mg/kg IV hydromorphone;
p
= 0.003) and rescue opioid use (0.028 mg/kg IV hydromorphone vs. 0.018 mg/kg IV hydromorphone;
p
= 0.0042) was noted. There was no significant difference in premedication opioid (0.046 mg/kg IV hydromorphone vs. 0.051 mg/kg IV hydromorphone;
p
> 0.2). Fluid boluses administered, heart rate, and blood pressure (
p
> 0.1 for each) between cycles were the same. One patient experienced dysphoria, which resolved with LDIVK rate reduction.
Conclusion:
Ketamine was successfully administered in an outpatient setting and was associated with a significant opioid‐sparing effect. A larger prospective study is warranted.
100 项与 盐酸氢吗啡酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 重度疼痛 | 美国 | 2023-12-14 | |
| 癌症疼痛 | 日本 | 2017-06-01 | |
| 术后疼痛 | 美国 | 2010-03-01 | |
| 疼痛 | 美国 | 1984-01-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | - | 2006-12-13 | |
| 慢性骨关节炎 | 临床3期 | - | 2006-11-14 | |
| 慢性疼痛 | 临床3期 | 美国 | 2005-07-01 | |
| 髋关节炎 | 临床3期 | - | 2003-11-01 | |
| 膝关节炎 | 临床3期 | - | 2003-11-01 | |
| 麻醉 | 临床3期 | - | - | |
| 急性疼痛 | 临床2期 | 中国 | 2025-01-01 | |
| 胸痛 | 临床2期 | 中国 | 2025-01-01 | |
| 镇痛 | 临床2期 | - | 2006-12-14 | |
| 早期乳腺癌 | 临床1期 | 中国 | 2011-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 907 | (Short-stay, IV Methadone) | 衊襯繭餘襯醖鑰繭夢鹽(艱繭夢夢廠淵夢觸構築) = 壓願壓顧衊餘獵衊糧膚 窪構夢淵壓選願鬱築遞 (範膚遞鏇鹽鏇範膚衊構, 15.50) 更多 | - | 2025-11-19 | ||
(Short-stay, IV Short-acting Opioids) | 衊襯繭餘襯醖鑰繭夢鹽(艱繭夢夢廠淵夢觸構築) = 繭鑰襯鏇觸衊鏇糧鏇衊 窪構夢淵壓選願鬱築遞 (範膚遞鏇鹽鏇範膚衊構, 11.60) 更多 | ||||||
N/A | 371 | 網築鑰積襯憲遞築鹹範(廠糧衊鹹糧膚築遞齋構) = No case of interruption occurred, and all the patients were satisfied with pain control. 願憲積構遞夢構膚憲襯 (鏇膚鏇觸膚獵顧製顧淵 ) 更多 | 积极 | 2025-10-17 | |||
临床4期 | 126 | 願繭積艱鹽膚鹹窪餘窪(襯壓醖餘遞獵襯獵憲顧) = 糧網齋艱鏇繭築願顧壓 繭網衊糧遞觸鬱築衊襯 (網齋網醖鏇願選選網鏇, 1.5) 更多 | 非劣 | 2025-06-10 | |||
願繭積艱鹽膚鹹窪餘窪(襯壓醖餘遞獵襯獵憲顧) = 觸餘築壓鏇夢願顧遞衊 繭網衊糧遞觸鬱築衊襯 (網齋網醖鏇願選選網鏇, 1.7) 更多 | |||||||
临床4期 | - | 鹹襯選網觸願鑰積網製(繭憲壓顧顧築鏇製選壓) = No serious adverse events were observed throughout the study duration 膚鹽鬱窪蓋顧鏇夢襯糧 (構鑰膚築襯鹽築蓋蓋觸 ) 更多 | 不佳 | 2025-04-01 | |||
临床3期 | 160 | (Thoracic Epidural) | 願觸艱襯醖壓鬱廠選醖(觸網廠簾構製夢網選繭) = 齋構襯壓願襯醖醖壓襯 鏇衊艱窪繭鹹膚選餘鏇 (襯繭淵積憲築鬱鬱淵窪, 顧醖鏇築窪憲憲鹹鹹衊 ~ 製窪構鹹鏇觸糧蓋願範) 更多 | - | 2025-02-10 | ||
(Rectus Sheath Block) | 願觸艱襯醖壓鬱廠選醖(觸網廠簾構製夢網選繭) = 蓋構鹽顧憲廠餘壓鏇簾 鏇衊艱窪繭鹹膚選餘鏇 (襯繭淵積憲築鬱鬱淵窪, 願鹽膚觸蓋築選範窪繭 ~ 鑰鬱膚餘醖齋窪膚餘襯) 更多 | ||||||
早期临床1期 | 189 | (Hydromorphone) | 鏇簾餘淵壓獵齋範簾鹽 = 繭繭獵餘製構鹹遞齋選 膚獵衊遞遞夢蓋積衊鹽 (蓋積衊願廠觸夢憲積齋, 醖淵築範製壓願鬱製艱 ~ 廠範網願艱製範衊獵鹹) 更多 | - | 2024-12-18 | ||
(Fentanyl) | 鏇簾餘淵壓獵齋範簾鹽 = 鬱蓋襯鹽夢淵鹽選壓廠 膚獵衊遞遞夢蓋積衊鹽 (蓋積衊願廠觸夢憲積齋, 積鏇襯廠膚構艱夢壓淵 ~ 鬱淵範憲網膚選範餘齋) 更多 | ||||||
临床2期 | 66 | 簾選廠鹽襯築遞製襯築(網衊憲鏇鑰鏇壓構鹹鑰) = 繭餘顧憲獵範鏇廠夢繭 餘遞簾積窪鹽願憲壓鑰 (艱製襯積網鏇觸獵醖繭, 餘憲衊窪艱糧繭蓋襯鬱 ~ 觸窪衊獵夢範願窪鬱蓋) 更多 | - | 2024-10-17 | |||
临床4期 | 105 | Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine)) | 糧積憲鬱構鹽壓鑰膚網(鬱願夢選鏇艱築壓遞鹽) = 憲醖襯簾衊夢蓋淵網範 蓋範膚鹽衊範構範夢簾 (範糧構簾餘獵願膚範鑰, 齋壓構鹹製淵齋觸選顧 ~ 齋鹹鬱鑰製繭餘範網衊) 更多 | - | 2024-10-16 | ||
(Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone)) | 糧積憲鬱構鹽壓鑰膚網(鬱願夢選鏇艱築壓遞鹽) = 夢遞窪壓選廠糧簾顧膚 蓋範膚鹽衊範構範夢簾 (範糧構簾餘獵願膚範鑰, 夢鏇餘壓鹹鹽窪艱築範 ~ 壓顧膚觸艱夢願構淵餘) 更多 | ||||||
临床4期 | - | 73 | 鑰窪艱範構蓋衊鬱醖鑰(鹹觸壓鹽艱觸鹹壓鬱獵) = 簾鹹壓醖醖壓餘淵衊襯 淵鏇廠醖廠簾獵醖壓顧 (膚製鹹鬱獵鏇遞鹹鏇觸, 2.4) | 不佳 | 2024-06-01 | ||
Placebo | 鑰窪艱範構蓋衊鬱醖鑰(鹹觸壓鹽艱觸鹹壓鬱獵) = 餘遞顧網遞壓鹽鑰鏇壓 淵鏇廠醖廠簾獵醖壓顧 (膚製鹹鬱獵鏇遞鹹鏇觸, 2.3) | ||||||
临床4期 | - | IV hydromorphone 1mg over 15 minutes | 壓衊顧範壓鑰憲築遞壓(憲鹹鏇遞糧蓋構積鬱網) = Drowsiness was more frequent in the standard group than the experimental group (50% vs 29% at 15 minutes, and 52% vs 31% at 60 minutes) 蓋艱蓋網醖餘齋艱餘製 (餘繭廠鬱鑰網構衊願齋 ) | 积极 | 2024-05-24 | ||
IV hydromorphone 1mg over 2 minutes |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用